These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 19279447

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
    Baldanti F, Paolucci S, Gulminetti R, Brandolini M, Barbarini G, Maserati R.
    J Med Virol; 2010 Jan; 82(1):116-22. PubMed ID: 19950236
    [Abstract] [Full Text] [Related]

  • 23. Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks.
    Sayana S, Prosser P, Ricaurte JC, Sanchez S, Hamwi G, Hershey-Weber J, Chien C, Easley A, Nguyen T, Wilson L, Khanlou H.
    J Int Assoc Physicians AIDS Care (Chic); 2009 Jan; 8(2):85-6. PubMed ID: 19369697
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
    Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, Galli A, Castagna A, Lazzarin A, Clementi M, Gianotti N.
    AIDS; 2009 Feb 20; 23(4):455-60. PubMed ID: 19165083
    [Abstract] [Full Text] [Related]

  • 27. [Integrase inhibition].
    Bogner JR.
    MMW Fortschr Med; 2009 Apr 30; 151(18):68-71. PubMed ID: 19769082
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Raltegravir as first integrase inhibitor in an HIV-infection].
    Papendorp SG, Brinkman K.
    Ned Tijdschr Geneeskd; 2009 Jan 31; 153(5):166-7. PubMed ID: 19256240
    [No Abstract] [Full Text] [Related]

  • 30. First-line raltegravir. No evidence of comparative effectiveness.
    Prescrire Int; 2010 Nov 31; 19(110):248-50. PubMed ID: 21284354
    [Abstract] [Full Text] [Related]

  • 31. Anti-HIV agents. Raltegravir (Isentress)--results after one year.
    TreatmentUpdate; 2007 Nov 31; 19(6):8-9. PubMed ID: 18041152
    [No Abstract] [Full Text] [Related]

  • 32. Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen.
    Delaugerre C, Charreau I, Braun J, Néré ML, de Castro N, Yeni P, Ghosn J, Aboulker JP, Molina JM, Simon F, ANRS 138 study group.
    AIDS; 2010 Sep 24; 24(15):2391-5. PubMed ID: 20683319
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Two studies show Kaletra and Isentress similarly suppress HIV, yet have different side effects.
    Proj Inf Perspect; 2009 Mar 24; (48):6. PubMed ID: 19492458
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. HIV integrase as a target for antiretroviral therapy.
    Hazuda DJ.
    Curr Opin HIV AIDS; 2012 Sep 24; 7(5):383-9. PubMed ID: 22871634
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.